| abstract |
FIELD: pharmaceutical industry.SUBSTANCE: invention relates to the pharmaceutical industry, namely to the use of a pharmaceutical composition including Liriope platyphylla root extract as an active ingredient for the prevention, treatment or mitigation of nicotine addiction, as well as to the use of a functional health product including Liriope platyphylla root extract as an active ingredient for the prevention, treatment or mitigation of nicotine addiction.EFFECT: above-described applications of the pharmaceutical composition can reduce the expression of the tyrosine hydroxylase (TH) protein and return it to normal level, increase the expression of the dopamine transporter protein (DAT) and return it to normal levels, and suppress the phenomenon of nicotine dependence, which increases locomotor activity.7 cl, 3 tbl, 3 ex, 8 dwg |